News
MNPR
109.09
-1.12%
-1.24
Weekly Report: what happened at MNPR last week (0720-0724)?
Weekly Report · 1d ago
BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup
TipRanks · 4d ago
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Ascendis Pharma (ASND) and Monopar Therapeutics Inc (MNPR)
TipRanks · 5d ago
Barclays Remains a Buy on Monopar Therapeutics Inc (MNPR)
TipRanks · 5d ago
MONOPAR THERAPEUTICS INC <MNPR.O>: PIPER SANDLER RAISES TARGET PRICE TO $123 FROM $101
Reuters · 5d ago
Monopar Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 6d ago
Monopar Therapeutics Price Target Raised to $125.00/Share From $105.00 by HC Wainwright & Co.
Dow Jones · 6d ago
HC Wainwright & Co. Maintains Buy on Monopar Therapeutics, Raises Price Target to $125
Benzinga · 6d ago
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125
TipRanks · 6d ago
Monopar price target raised to $125 from $105 at H.C. Wainwright
TipRanks · 6d ago
MONOPAR THERAPEUTICS INC. <MNPR.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $125 FROM $105
Reuters · 6d ago
Monopar Begins Rolling FDA NDA Submission for ALXN1840
TipRanks · 6d ago
Monopar Therapeutics initiates rolling ALXN1840 NDA submission to FDA
TipRanks · 6d ago
Monopar Therapeutics Begins Rolling Submission Of FDA New Drug Application For ALXN1840 Albumin Tripartite Complex Activator To Treat Wilson Disease
Benzinga · 6d ago
Monopar starts rolling FDA NDA submission for ALXN1840 in Wilson disease
PUBT · 6d ago
MONOPAR INITIATES ROLLING NDA SUBMISSION FOR ALXN1840 IN WILSON DISEASE
Reuters · 6d ago
Biotech Stocks At 52-Week Highs - XNCR, COAG, MNPR, SOPH, ACRS
NASDAQ · 07/21 07:41
Monopar adds ex-KalVista CCO Nicole Sweeny to board
PUBT · 07/20 12:02
Press Release: Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team
Dow Jones · 07/20 12:00
*Monopar Appoints Nicole Sweeny to Board of Directors
Dow Jones · 07/20 12:00
More
Webull provides a variety of real-time MNPR stock news. You can receive the latest news about Monopar Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About MNPR
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.